Erudio Healtherudio.com
Indication
HER2-negative breast cancer trials: what clinicians said in public
No HCP commentary report on a trial in HER2-negative breast cancer yet. Erudio has found public clinician commentary on 18 clinical trials in HER2-negative breast cancer, including I-SPY, OFSET, ROSALINE and TRADE-DXd. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| I-SPY NCT01042379 · QuantumLeap Healthcare Collaborative DeepView → | early-stage or locally advanced breast cancer | Phase 2 | Deep | View | |||
| TRADE-DXd NCT06533826 · Ana C Garrido-Castro, MD DeepView → | ADC-refractory HER2-negative metastatic breast cancer | Phase 2 | Deep | View | |||
| ROSALINE NCT04551495 · Jules Bordet Institute DeepView → | ER+ HER2-negative invasive lobular breast carcinoma | Phase 2 | Deep | View | |||
| OFSET NCT05879926 · NRG Oncology DeepView → | premenopausal ER-positive/HER2-negative breast cancer, Oncotype recurrence score ≤25 | Phase 3 | Deep | View | |||
| TROPION-Breast01 NCT05104866 · AstraZeneca DeepView → | previously treated inoperable/metastatic HR-positive, HER2-negative breast cancer | Phase 3 | Deep | View | |||
| SASCIA NCT04595565 · GBG Forschungs GmbH DeepView → | high relapse risk primary HER2-negative breast cancer | Phase 3 | Deep | View | |||
| TREAT ctDNA NCT05512364 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | ER+/HER2- breast cancer with ctDNA relapse | Phase 3 | Deep | View | |||
| DATO-BASE NCT06176261 · Nancy Lin, MD DeepView → | Not given | Phase 2 | Deep | View | |||
| FAKTION NCT01992952 · Velindre NHS Trust StandardView → | metastatic estrogen receptor-positive HER2-negative breast cancer | Phase 1/Phase 2 | Standard | View | |||
| TRAK-ER NCT04985266 · Royal Marsden NHS Foundation Trust StandardView → | ER-positive HER2-negative breast cancer with molecular relapse | Phase 2 | Standard | View | |||
| ADELA NCT06382948 · MedSIR StandardView → | ESR1-mutated ER+/HER2- advanced breast cancer after CDK4/6 inhibitors | Phase 3 | Standard | View | |||
| PROMETEO NCT03802604 · SOLTI Breast Cancer Research Group StandardView → | residual HER2-negative breast cancer after neoadjuvant chemotherapy | Early phase 1 | Standard | View | |||
| SWITCH NCT06649331 · Fudan University FocusedView → | ADC-treated metastatic breast cancer | Phase 2 | Focused | View | |||
| CAPELA NCT07222215 · Kristina A. Fanucci FocusedView → | advanced estrogen receptor-positive HER2-negative breast cancer | Phase 2 | Focused | View | |||
| FITWISE NCT06518837 · Rutgers, The State University of New Jersey FocusedView → | early-stage hormone receptor-positive HER2-negative breast cancer | Phase 2 | Focused | View | |||
| IPATunity130 NCT03337724 · Hoffmann-La Roche FocusedView → | PIK3CA/AKT1/PTEN-altered advanced HER2-negative breast cancer | Phase 3 | Focused | View | |||
| NeoSTAR NCT04230109 · Massachusetts General Hospital FocusedView → | localized triple-negative breast cancer | Phase 2 | Focused | View | |||
| ERADICATE NCT07198724 · Kristina A. Fanucci FocusedView → | endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic breast cancer | Phase 1/Phase 2 | Focused | View | |||